BRCA2 and breast cancer: Considering the non-negligible prevalence of pathogenic germline variants in genes involved in DNA repair mechanisms in men with BC, especially BRCA2, the use of poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) is of particular interest.